SOHO 2023

Selected news on Chronic Lymphocytic Leukemia from the SOHO 2023 Annual Meeting.

Real-world Outcomes of Ibrutinib Dose Reduction Versus No Reduction After AEs
Real-world Outcomes of Ibrutinib Dose Reduction Versus No Reduction After AEs
Patrick DalySOHO 2023 | September 14, 2023
Patients with ibrutinib dose reduction after an AE had longer treatment length and similar efficacy versus no dose reduction.
Defining Disease Features, Treatment Options in Patients With CLL
Defining Disease Features, Treatment Options in Patients With CLL
Patrick DalySOHO 2023 | September 14, 2023
A study on patterns in patients with CLL found the RFC regimen appeared to be most effective for OS and response rates.
Difference in Anxiety Levels Between Oral, Intravenous Treatment in Patients With CLL
Difference in Anxiety Levels Between Oral, Intravenous Treatment in Patients With CLL
Patrick DalySOHO 2023 | September 14, 2023
Patients with chronic lymphocytic leukemia experience more anxiety when receiving intravenous versus oral treatments.
Venetoclax Efficacy in Patients With CLL Who Relapsed After HSCT
Venetoclax Efficacy in Patients With CLL Who Relapsed After HSCT
Patrick DalySOHO 2023 | September 14, 2023
Patients with CLL who relapsed after HSCT and then received venetoclax therapy achieved outcomes consistent with trial data.
Advertisement
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Contribute

    Contact Us

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2024 Mashup Media, LLC. All rights reserved.

    Terms of Use | Privacy Policy